Delving into the Latest Updates on Fluocinonide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Fluocinonide (JP17/USP/INN), Fluocinonide Cream, Fluocinonide Gream

+ [8]

Target

GR

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesCongenital Disorders+ [5]

Active Indication

Alopecia AreataImpetigoPrurigo+ [11]

Inactive Indication-

Originator Organization

County Line Pharmaceuticals LLC

Active Organization

Tianjin Jinyao Pharmaceutical Co., Ltd.

Mayinglong Pharmaceutical Group Co., Ltd.Mitsubishi Tanabe Pharma Factory Ltd.

+ [3]

Inactive Organization

Medicis Pharmaceutical Corp.

Drug Highest PhaseApproved

First Approval Date

US (30 Jun 1971),

InflammationPruritus

Regulation-

Login to view timeline

Structure

Molecular FormulaC26H32F2O7

InChIKeyWJOHZNCJWYWUJD-IUGZLZTKSA-N

CAS Registry356-12-7

This is a Phase 2, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatment for atopic dermatitis (AD). The trial will enroll adults and adolescents with atopic dermatitis who are culture positive for S. aureus colonization. The primary objective of this study is to assess the ability of ShA9, compared to placebo (vehicle), to prolong the period of atopic dermatitis control over 12 weeks after conclusion of an initial two-week period of co-treatment with topical corticosteroids (TCS).

Start Date15 Dec 2024

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

[+2]

NCT06135805 / CompletedNot ApplicableIIT

Impact of the Efficacy of Fluocinonide 0.05% Oral Gel in the Treatment of Oral Lichen Planus

A double-blind placebo-controlled trial is conducted in order to evaluate the efficacy of Fluocinonide 0,05% and determinate the statistical significance of the outcome variables. Oral cavity lichen is a chronic inflammatory condition affecting the mucosa of the oral cavity , which significantly reduces the quality of life of affected individuals.

Start Date20 Aug 2023

Sponsor / Collaborator

University of Catania

NCT02301494 / WithdrawnNot ApplicableIIT

Feasibility Study to Determine Effectiveness of 3.75% Topical Imiquimod Cream and Topical Vanos (Fluocinonide) Cream 0.1% in the Treatment of Early Stage Cutaneous T-cell Lymphoma

This study is being conducted by Brian Poligone, MD PhD. The purpose of this study is to determine safety, effectiveness, and tolerability of two topical therapies, imiquimod and fluocinonide, for patients with early stage Cutaneous T-cell Lymphoma (CTCL).

Start Date01 Apr 2020

Sponsor / Collaborator

Rochester General Hospital

[+2]

100 Clinical Results associated with Fluocinonide

Login to view more data

100 Translational Medicine associated with Fluocinonide

Login to view more data

100 Patents (Medical) associated with Fluocinonide

Login to view more data

215

Literatures (Medical) associated with Fluocinonide

01 Dec 2024·International Journal of Pharmaceutics

Development and biopharmaceutical evaluation of aqueous micelle based corticosteroid formulations for topical treatment of oral lichen planus

Article

Author: Kalia, Yogeshvar N ; Suter, Valerie G A ; Suter, Valerie G.A. ; Tyagi, Vasundhara ; Kalia, Yogeshvar N. ; Lapteva, Maria ; Kandekar, Somnath

The dearth of approved products to treat oral lichen planus (OLP) compels off-label use of dermatological corticosteroid formulations not optimized for indications in the oral cavity. The aims of this study were to develop aqueous micelle based formulations of triamcinolone acetonide (TA) and fluocinonide (FLU), using D-tocopheryl polyethylene glycol succinate, and to investigate corticosteroid delivery to the epithelium-lamina propria junction region - the anatomical target for OLP treatment - in comparison to that from marketed products. Total mucosal deposition of TA after application of Kenacort® A Orabase® (0.1 % TA) and micellar hydrogel (0.1 %) was 242.1 ± 68.5 and 5936.7 ± 1269.6 ng/cm², respectively. For FLU, deposition after application of Novoter (0.05 % FLU) and micellar hydrogel (0.05 %) was 617.1 ± 126.5 and 2580.0 ± 285.5 ng/cm², respectively. A buccal biodistribution study showed that application of micelle hydrogels under occlusion for 30 min delivered 117.0 ± 15.6 ng/cm² and 225.6 ± 36.7 ng/cm², of TA and FLU, respectively, to the epithelium-lamina propria junction region. In contrast, the amounts deposited after applying Kenacort® A Orabase® and Novoter, were < LOQ. The results demonstrated that TPGS-based micelles improved mucosal bioavailability of TA and FLU in the epithelium-lamina propria junction region and might serve to improve topical OLP therapy.

24 Apr 2023·Journal of chemical information and modeling

DrugRep-KG: Toward Learning a Unified Latent Space for Drug Repurposing Using Knowledge Graphs.

Article

Author: Salehi, Najmeh ; Masoudi-Nejad, Ali ; Ghorbanali, Zahra ; Akbari, Mohammad ; Zare-Mirakabad, Fatemeh

Drug repurposing or repositioning (DR) refers to finding new therapeutic applications for existing drugs. Current computational DR methods face data representation and negative data sampling challenges. Although retrospective studies attempt to operate various representations, it is a crucial step for an accurate prediction to aggregate these features and bring the associations between drugs and diseases into a unified latent space. In addition, the number of unknown associations between drugs and diseases, which is considered negative data, is much higher than the number of known associations, or positive data, leading to an imbalanced dataset. In this regard, we propose the DrugRep-KG method, which applies a knowledge graph embedding approach for representing drugs and diseases, to address these challenges. Despite the typical DR methods that consider all unknown drug-disease associations as negative data, we select a subset of unknown associations, provided the disease occurs because of an adverse reaction to a drug. DrugRep-KG has been evaluated based on different settings and achieves an AUC-ROC (area under the receiver operating characteristic curve) of 90.83% and an AUC-PR (area under the precision-recall curve) of 90.10%, which are higher than in previous works. Besides, we checked the performance of our framework in finding potential drugs for coronavirus infection and skin-related diseases: contact dermatitis and atopic eczema. DrugRep-KG predicted beclomethasone for contact dermatitis, and fluorometholone, clocortolone, fluocinonide, and beclomethasone for atopic eczema, all of which have previously been proven to be effective in other studies. Fluorometholone for contact dermatitis is a novel suggestion by DrugRep-KG that should be validated experimentally. DrugRep-KG also predicted the associations between COVID-19 and potential treatments suggested by DrugBank, in addition to new drug candidates provided with experimental evidence. The data and code underlying this article are available at https://github.com/CBRC-lab/DrugRep-KG.

01 Dec 2022·BMC Oral Health

Oral lichen planus: comparative efficacy and treatment costs—a systematic review

Review

Author: Hussein, Mai ; Klein, Brittany A ; Vacharotayangul, Piamkamon ; Sonis, Stephen ; Treister, Nathaniel ; Al-Hadlaq, Malak ; Bajonaid, Amal ; Sroussi, Herve ; Sandhu, Shaiba ; Xu, Yuanming ; Chirravur, Prazwala ; Intini, Rossella

AbstractObjectiveTo compare the reported efficacy and costs of available interventions used for the management of oral lichen planus (OLP).Materials and methodsA systematic literature search was performed from database inception until March 2021 in MEDLINE via PubMed and the Cochrane library following PRISMA guidelines. Only randomized controlled trials (RCT) comparing an active intervention with placebo or different active interventions for OLP management were considered.ResultsSeventy (70) RCTs were included. The majority of evidence suggested efficacy of topical steroids (dexamethasone, clobetasol, fluocinonide, triamcinolone), topical calcineurin inhibitors (tacrolimus, pimecrolimus, cyclosporine), topical retinoids, intra-lesional triamcinolone, aloe-vera gel, photodynamic therapy, and low-level laser therapies for OLP management. Based on the estimated cost per month and evidence for efficacy and side-effects, topical steroids (fluocinonide > dexamethasone > clobetasol > triamcinolone) appear to be more cost-effective than topical calcineurin inhibitors (tacrolimus > pimecrolimus > cyclosporine) followed by intra-lesional triamcinolone.ConclusionOf common treatment regimens for OLP, topical steroids appear to be the most economical and efficacious option followed by topical calcineurin inhibitors. Large-scale multi-modality, prospective trials in which head-to-head comparisons interventions are compared are required to definitely assess the cost-effectiveness of OLP treatments.

100 Deals associated with Fluocinonide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00325	Fluocinonide	C05AA11 D07AC08	DB01047

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Alopecia Areata	JP	Mitsubishi Tanabe Pharma Factory Ltd.	01 May 2020
Impetigo	JP	Mitsubishi Tanabe Pharma Factory Ltd.	01 May 2020
Prurigo	JP	Mitsubishi Tanabe Pharma Factory Ltd.	01 May 2020
Vitiligo	JP	Mitsubishi Tanabe Pharma Factory Ltd.	01 May 2020
Plaque psoriasis	US	Bausch Health US LLC	11 Feb 2005
Dermatitis, Atopic	CN	Mayinglong Pharmaceutical Group Co., Ltd.	01 Jan 1981
Dermatitis, Contact	CN	Mayinglong Pharmaceutical Group Co., Ltd.	01 Jan 1981
Dermatitis, Contact	CN	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981
Dermatitis, Seborrheic	CN	Mayinglong Pharmaceutical Group Co., Ltd.	01 Jan 1981
Dermatitis, Seborrheic	CN	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981
Eczema	CN	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981
Eczema	CN	Mayinglong Pharmaceutical Group Co., Ltd.	01 Jan 1981
Neurodermatitis	CN	Mayinglong Pharmaceutical Group Co., Ltd.	01 Jan 1981
Neurodermatitis	CN	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981
Psoriasis	CN	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981
Psoriasis	CN	Mayinglong Pharmaceutical Group Co., Ltd.	01 Jan 1981
Inflammation	US	Alvogen, Inc.	30 Jun 1971
Pruritus	US	Alvogen, Inc.	30 Jun 1971

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic macular oedema	Phase 3	CN	Ocumension Suzhou Biotech Co., Ltd.	30 Jan 2022
Dermatitis, Atopic	Phase 2	US	Medicis Pharmaceutical Corp.	01 Feb 2012
Pruritus	Phase 2	US	Medicis Pharmaceutical Corp.	01 Feb 2012

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01802580 (CTgov)	Early Phase 1	Psoriasis	40	Internet Survey+fluocinonide 0.05% ointment (Intervention - Internet Reminder Survey)	oypfoanaor(eedlzqmsxo) = iutqwppcky lsvppasghz (khcfvxnjtw, evkkrghzog - gmccultfvq) View more	-	12 Nov 2019
NCT01802580 (CTgov)	Early Phase 1	Psoriasis	40	fluocinonide 0.05% ointment (Standard of Care, no Internet Survey)	oypfoanaor(eedlzqmsxo) = rrxijtogym lsvppasghz (khcfvxnjtw, ixikyadwmw - nlhiamczgw) View more	-	12 Nov 2019
NCT01422408 (CTgov)	Phase 2	vaginal mucosa dry \| Dyspareunia \| Invasive Mammary Carcinoma	34	Management of Therapy Complications+Fluocinonide Cream	ecdinbmvju(bfqebrbuex) = hnjnrgaato cntoxshagx (djidgajjxx, zijmgoqxco - rvndzjbcrg) View more	-	09 Aug 2017
NCT00819507 (CTgov)	Phase 4	Dermatitis, Atopic	25	Fluocinonide	ohqkrsxvxg(pjmglkrjfo) = eyqxlvwgzg burnxgijyc (skrjigwubm, wqkugvxoqc - orqcpdqpci) View more	-	11 Jul 2017
NCT01469767 (CTgov)	Phase 2	Pruritus \| Dermatitis, Atopic	10	Fluocinonide cream	lbdviyebqf(dbdmcwrmld) = rdhydymbfo aisdhtlikp (oflatrabjr, xaqqkuspub - zzdwwqwchk) View more	-	01 May 2017